MetaCap

Cocrystal Pharma (COCP) vs IGC Pharma (IGC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cocrystal Pharma (COCP) has outperformed IGC Pharma (IGC) over the past year, gaining 5.6% versus a loss of 47.5%. Over five years, IGC leads with a -87.6% price change compared with -91.8% for COCP. IGC Pharma is the larger company by market cap ($19.6 million vs $18.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COCP+5.56%IGC-47.50%
+81%+13%-54%
Nov 21, 20251 yearNov 20, 2026
COCP-90.35%IGC-88.25%
+24%-37%-97%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COCP versus IGC key metrics
MetricCOCPIGC
Share price$0.95$0.168
Market cap$18.30M$19.60M
1-day change-2.05%-8.70%
YTD return-3.06%-40.00%
1-year return+5.56%-47.50%
5-year return-91.84%-87.65%
EPS (TTM)$-0.76$-0.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.27M
Revenue growth (YoY)—-5.50%
Net income (latest FY)$-8.83M$-7.12M
Gross margin—48.70%
Operating margin—-585.84%
Net margin—-560.35%
52-week high$2.03$0.36
52-week low$0.76$0.08
Distance from 52-week high-53.20%-53.33%
Analyst consensusnonenone
Avg. price target upside+847.37%+3471.43%
Average volume40.65K615.25K
Shares outstanding19.26M116.69M
Employees1070
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • COCP has outperformed IGC by 53.1 percentage points over the past year.

About Cocrystal Pharma

COCP stock →

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

About IGC Pharma

IGC stock →

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.

Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees

COCP vs IGC FAQ

Which is bigger, Cocrystal Pharma or IGC Pharma?

IGC Pharma (IGC) is larger, with a market capitalization of $19.60M compared with $18.30M for Cocrystal Pharma (COCP).

Which stock has performed better over the past year, COCP or IGC?

COCP returned +5.56% over the past 12 months, compared with -47.50% for IGC (price return, excluding dividends). Past performance does not predict future results.

Are Cocrystal Pharma and IGC Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons